FDA Warns Compounded GLP-1 Drugs Have Dosing Issues, Adverse Events

FDA issued a warning Monday (July 29) to patients and health care providers about dosing issues with compounded versions of the type-2 diabetes and obesity drugs Ozempic and Wegovy, following reports of adverse events including acute pancreatitis and gallstones, abdominal pain and fainting. In March, sources told Inside Health Policy that some telehealth companies were marketing these compounded drugs at lower prices than brand-name drugs to make substantial profits and amid brand-name product shortages. FDA officials said the adverse...